… Andy Surinachc Genesis Research, Hoboken, NJ, USA … A Surinach is an employee of
Genesis Research, which has received consulting fees from Pfizer. …

Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic
target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for …

Objectives Liposomal irinotecan (nal-IRI) is a topoisomerase inhibitor proven to improve
survival in metastatic pancreatic cancer (mPC). This study describes real-world characteristics …

Background The purpose of this study was to understand how the COVID-19 pandemic has
affected health care patterns and outcomes for patients diagnosed with metastatic pancreatic …

… Mr Surinach reported receiving consulting fees from Pfizer, Inc. Mr Chambers being
employed by Pfizer, Inc. Mr Benigno reported being employed by and owning stock in Pfizer, Inc. …

Background: Few studies have addressed the cost patterns of patients with multiple myeloma
(MM) before and after first relapse. This US claims analysis evaluated, from a US health …

Background Neuromyelitis optica spectrum disorder (NMOSD) is associated with various
comorbidities, including non-autoimmune and autoimmune conditions. The burden and cost of …

Background Pancreatic cancer is expected to be the third deadliest cancer in the US in 2021.
Evaluation of treatment response in patients with mPDAC necessitates scheduled clinical …

Background Since Food and Drug Administration approval of brentuximab vedotin in combination
with cyclophosphamide, doxorubicin, and prednisone (A + CHP) as initial therapy for …

Multiple myeloma (MM) treatment options have evolved rapidly, but how new agents are
incorporated into treatment decisions in current practice is not well understood. This study …